

Performance in Delivering Q3 14/15 29.01.15

Id	Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
39607	12/NN/0341	A double-blind, randomised, placebo-controlled, multicentre study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident carotid	Available	22	Available	08/03/2015	Open	N/A	
39608	13/NN/0054	A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis	Available	20	Available	20/03/2014	Closed - Follow Up Complete	Y	
39610	13/NI/0044	A study to measure Serum Periostin, asthma-related biomarkers and response to Prednisolone in adult and adolescent patients with severe oral corticosteroid-dependent asthma.	Available	9	Available	15/10/2013	Closed - Follow Up Complete	N	Serum Periostin follow on study started (Vocals) so recruitment ended
39611	13/NN/0215	A double blind, randomized, placebo controlled phase II study to assess the efficacy of recPRAME +AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected PRAME-positive, Non-Small Cell Lung Cancer (PEARL-PRAME)	Available	4	Available	01/08/2014	Closed - Follow Up Complete	Y	closed early (august 2014)
39612	13/LO/0501	A Phase 2, randomized, dose-ranging study to assess the safety and anti-cytomegalovirus (CMV) activity of Maribavir versus Valganciclovir for the treatment of CMV infections in transplant recipients who do not have cmv organ disease. Maribavir Study.	Available	10	Available	14/02/2014	Closed - Follow Up Complete	N	original recruitment period was june 2014 this was cut short
39613	13/NN/0234	A prospective, Multicentre, Controlled Study of implant-based breast reconstruction, measuring the safety, effectiveness and cost consequences, of Immediate Single Stage Breast Reconstruction with Strattice Reconstructive Tissue Matrix versus Immediate Two	Available	10	Available	07/07/2014	Closed - In Follow Up	Y	
39614	13/NN/0462	Randomised, double-blind, dose-finding Phase II study to assess the efficacy of APD403 in the prevention of nausea and vomiting caused by cisplatin - or anthracycline / Cyclophosphamide (AC)-based chemotherapy	Available	10	Available	01/11/2014	Open	Y	
39615	13/EM/0230	A Phase II Randomised, Double-Blind, Placebo-Controlled, Multicenter study of VS6063 in subjects with Malignant Pleural Mesothelioma	Available	10	Available	01/03/2015	Open	Y	
39616	13/NN/0586	A study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550mg TID in Subjects with Irritable Bowel Syndrome with Diarrhoea (IBS-D)	Available	20	Available	30/03/2015	Closed - Follow Up Complete	Y	original agreed date for recruitment was end of march then company closed study early
39617	13/YH/0232	A randomised double-blind (sponsor-unblind) placebo controlled, cross-over study to investigate the efficacy, effect on cough reflex sensitivity, safety, tolerability and pharmacokinetics of inhaled GSK2339345 in patients with chronic idiopathic cough using an aqueous droplet inhaler. Echo	Available	10	Available	18/08/2014	Closed - Follow Up Complete	Y	original target was 20 patients, this target was reduced to 10 during the study
39618	13/SC/0348	A randomised, open label Phase II study evaluating LY2875358 plus Erlotinib and LY2875358 monotherapy in MET diagnostic positive NSCLC patients with acquired resistance to Erlotinib	Available	1	Available	01/08/2014	Closed - Follow Up Complete	N	closed early in august 2014
39619	13/LO/0219	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER)	Available	3	Available	15/04/2015	Open	N/A	July 2014 was the original date for end of recruitment this has been extended and we are still open to recruitment
39620	13/LO/1121	A randomized, controlled phase 2 study evaluating LY2875358 plus Erlotinib versus Erlotinib as first-line treatment in Metastatic non-small cell lung cancer patients with activating EGFR mutations who have disease control after 8-week lead-in treatment with Erlotinib	Available	6	Available	01/11/2014	Open	N/A	extremely niche study and not enough patients on erlotinib
39621	13/NE/0094	Phased RF Evaluation of Acute Pulmonary Vein Isolation in Paroxysmal AF with new GENUS UI and PVAC GOLD	Available	10	Available	01/06/2014	Closed - Follow Up Complete	N	original recruitment date july 2014
39622	13/NN/0283	GLOBAL LEADERS: Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a current-day intensive dual anti-platelet therapy in all-comers patients undergoing percutaneous coronary intervention with bivalirudin and Biomatrix family drug-eluting stent use.	Available	150	Available	01/06/2015	Open	N/A	
39623	13/LO/1348	Lutonix	Available	13	Available	31/07/2014	Closed - In Follow Up	Y	original target was 20-24 with an end of recruitment date of 1/6/15 the target and end of recruitment date was reduced
39624	13/NI/0148	A phase II, randomised, double-blind, placebo-controlled, multicentre trial to assess the oral corticosteroid-sparing effect of lebrikizumab in patients with severe corticosteroid-dependent asthma - VOCALS	Available	12	Available	01/01/2015	Open	Y	
39625	13/WM/0235	Atrial Fibrillation Progression Trial (ATTEST Trial)	Available	5	Available	01/03/2015	Open	N/A	
39626	13/NN/0583	A 24 Week International, Multi-center, Randomised, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Inpatients with Type 2 Diabetes who have Inadequate Glycaemic Control with Diet and Exercise	Available	5	Available	01/03/2015	Open	N/A	
39627	13/SS/0044	Efficacy and safety of lidocaine 5% medicated plaster in localised chronic post-operative neuropathic pain	Available	6	Available	30/04/2016	Open	N/A	
39628	13/SC/0384	A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second-or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma	Available	10	Available	01/11/2014	Open	Y	
39629	13/YH/0282	Open-label, Phase IIIb study to evaluate the efficacy and safety of subcutaneous (SC) Tocilizumab monotherapy or combination therapy with methotrexate (MTX) or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with severe Rheumatoid Arthritis (RA) who are being treated with an anti-tumour necrosis factor (anti-TNF) agent and that have not achieved an adequate response to treatment	Available	5	Available	01/07/2015	Open	N/A	
39630	13/EE/0326	REVACEPT, AN INHIBITOR OF PLATELET ADHESION IN SYMPTOMATIC CAROTID STENOSIS: A PHASE II, MULTICENTRE, RANDOMISED, DOSE-FINDING, DOUBLE-BLIND AND PALCEBO-CONTROLLED SUPERIORITY STUDY WITH PARALLEL GROUPS	Available	48	Available	01/08/2015	Open	N/A	
39631	13/NN/0612	Benralizumab treatment in patients with uncontrolled asthma (SIRIOCCO)	Available	1	Available	23/05/2016	Open	Y	
39632	13/WA/0084	CV Outcomes following Treatment with MK3102 in Subjects with T2DM	Available	7	Available	01/10/2014	Closed - Follow Up Complete	N	original date agreed to recruit target number of patients cut short
39634	12/EM/0284	A multi-centre, open-label, long-term safety study of meplizumab in asthmatic subjects who participated in the MEA112997 trial.	Available	3	Available	18/02/2013	Closed - In Follow Up	N	this study was a follow on study and only patients that had taken part in the initial study were eligible. Not all patients wanted to take part in this study.
39635	14/ES/0001	Enugifozin in participants with T2DM & Vascular disease	Available	11	Available	01/06/2015	Open	N/A	
39636	13/LO/0867	1199.93 - Nintedanib in Mesothelioma	Available	4	Available	01/12/2014	Open	Y	
39637	14/EM/0024	A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 3 years in subjects with active Psoriatic Arthritis	Available	3	Available	22/09/2014	Closed - In Follow Up	Y	
39638	14/NE/0016	IRIS-3: A 12 week double-blind, randomised, placebo-controlled, parallel group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral lisdexamfetamine 10mg once daily in female patients with Irritable Bowel Syndrome with Diarrhoea (IBS-D)	Available	10	Available	01/09/2015	Open	N/A	
39639	14/NN/0211	A double-blind, randomised, placebo-controlled, crossover study to assess the efficacy of XEN-D0501, a TRPV1 antagonist, in reducing the frequency of cough in patients with chronic idiopathic cough.	Available	10	Available	01/03/2015	Open	N/A	
39642	14/WS/0004	Open-label Extension Study of EFC12492, R727-CL-1112, EFC12732 & LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia	Available	2	Available	01/09/2014	Closed - In Follow Up	Y	
39643	14/NN/0008	Golimimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis	Available	6	Available	30/03/2015	Open	N/A	
39644	14/LO/0521	A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID	Available	2	Available	31/03/2015	Open	N/A	
39645	14/SW/0091	Randomized, Double-blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non Small Cell Lung Cancer (NSCLC)	Available	4	Available	01/09/2015	Open	N/A	
40584	10/H07216	UBIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes. Assessment of adults with severe asthma	Available	94	Available	01/11/2012	Closed - In Follow Up	N	
40585	11/H1003/9	A Sideguard Coronary Sidebranch Registry: A post market registry to observe the clinical outcomes of the Bare Metal Sideguard® Coronary Sidebranch stent in de novo Bifurcation Lesions of Native Coronary Arteries	Available	10	Available	31/03/2013	Closed - Follow Up Complete	N	sponsor closed study early as they had reached their required numbers
40586	08/H0711/4	A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification in patients with advanced/metastatic non-small cell lung cancer	Available	4	Available	01/07/2014	Closed - Follow Up Complete	Y	original target of 5 over 3 years (5 a year) recruitment was closed a year early and target reduced to 2 a year
40587	12/NN/0002	A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Erlibulin with Treatment of Physician's Choice in Subjects with Advanced Non-Small Cell Lung Cancer (Elevate)	Available	6	Available	01/05/2015	Closed - Follow Up Complete	Y	
40588	12/NN/0431	A multi-centre, open-label, adaptive, randomised study of Palifosfamide-tris, a novel DNA Crosslinker, in combination with Carboplatin and Etoposide (PaCE) chemotherapy versus Carboplatin and Etoposide (CE) alone in chemotherapy naive patients with extens	Available	12	Available	01/09/2014	Closed - In Follow Up	N	recruitment was on track but sponsor closed study due to financial reasons
40589	12/EE/0371	A multi-centre, randomised, active-controlled efficacy and safety study comparing extended duration Betrixaban with standard of care Enoxaparin® for the prevention of venous thromboembolism in acute medically ill patients	Available	320	Available	30/09/2015	Open	N/A	
40590	14/SC/1097	A randomised controlled trial of the effect of intermittent energy restriction (IER) versus daily energy restriction (DER) on body fat stores and cancer related biomarkers	Available	26	Available	30/07/2015	Open	N/A	
40591	14/LO/1513	A randomized, Open-Label, Phase 4 Study Evaluating the Renal Effect of Efavirenz/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/T	Available	3	Available	31/12/2015	Open	N/A	